Biotechnology APAC News & Press Release Distribution

Biotechnology

All
Global

Call for Application for 2025 Tsinghua Amgen Scholars Program

BEIJING, Dec. 11, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...

2024-12-11 14:33 2344

Call for Application for 2025 Tsinghua Amgen Scholars Program

2024 PHBS-CJBS Global Pitch Competition Grand Final Held

SHENZHEN, China, Dec. 11, 2024 /PRNewswire/ -- The 2024 PHBS-CJBS Global Pitch Competition, jointly hosted by Peking University HSBC Business School (PHBS) and Cambridge Judge Business School (CJBS), concluded with its grand final on December 5th at PHBS in Shenzhen, China. During the finals...

2024-12-11 12:29 1362

2024 PHBS-CJBS Global Pitch Competition Grand Final Held

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that Prof.Weiming Li, ...

2024-12-10 21:27 1776

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

2024-12-10 20:48 1679

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-12-10 08:30 1571

Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients withHuntington's Disease Volumetric MRI measurement is also approved as exploratory study endpoint BOSTON, Dec. 10, 2024 /PRNewswire/ -- Skyhawk Therapeu...

2024-12-10 00:47 1445

Seoul National University Bundang Hospital Establishes the first "International PSP Research and Treatment Center" in Korea

* MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center * Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and treatment hub for the rare neurodegenerative disease" SEOUL, South Korea, Dec. 9, 2024 /PRNe...

2024-12-09 22:00 2067

Seoul National University Bundang Hospital Establishes the first

MGI Tech's Innovative Sequencing Technology Drives Mangrove Conservation Efforts in Thailand

Link to Thailand's mangrove ecosystem conservation project video: https://youtu.be/12xOTDxgMPw BANGKOK, Dec. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, ha...

2024-12-09 15:34 1765

Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. * CS5001 is well tolerated in heavily...

2024-12-09 08:20 1647

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2024-12-09 08:00 1863

Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations

BEIJING, Dec. 6, 2024 /PRNewswire/ -- Qi Biodesign, a biotechnology company pioneering next-generation genome editing technologies, announced the completion of its Series A funding round. The company has now raised a total of $75 million across its Seed, Series Pre-A, and Series A stages. The Seri...

2024-12-06 20:15 6786

SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center

* SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 * Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ13731...

2024-12-06 09:00 2009

SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center

Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in theAsia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sens...

2024-12-06 08:07 1838

Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

IonOpticks' Custom Chromatography Column to Become Biognosys' Standard for High-Quality Proteomic Insights

MELBOURNE, Australia and ZURICH, Dec. 6, 2024 /PRNewswire/ -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonO...

2024-12-06 05:00 2033

Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services

* Mission Launched via SpaceX CRS-31; Experiment Now Underway on the ISS * Collaboration Aims to Enhance Healthspan on Earth and Improve Astronaut Health in Space * IM8, a new premium supplements brand launched officially on November 18th on IM8health.com CHARLOTTE, N....

2024-12-05 21:30 2205

Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.

* First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). * FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devicesthat could provide more effe...

2024-12-05 21:03 1608

Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

EAST RUTHERFORD, N.J., Dec. 5, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly...

2024-12-05 19:00 1374

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key...

2024-12-05 11:59 1521

Veeva Pulse Data Shows New Science Calls for More Connected Engagement

Synchronizing sales and marketing improves outcomes, yet 65% of field engagements are not SINGAPORE, Dec. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today released its latestVeeva Pulse Field Trends Report

2024-12-05 09:00 1646

Veeva Pulse Data Shows New Science Calls for More Connected Engagement

Former CSL CEO Paul Perreault appointed strategic adviser to Microbio

Establishing sepsis diagnostic InfectID™ as the new standard of care BRISBANE, Australia, Dec. 5, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has today announced the appointment ofPaul Perreault as a st...

2024-12-05 06:30 1744

1 234 5 6 ... 180